These data indicate that radio‐resistant hepatic cells are primary targets of IFNα necessary for the Tie2‐IFNα‐based therapy to perform its full anti‐metastatic potential, which likely involves additional anti‐tumor activities mediated by BM‐derived immune cells (including TEMs themselves), consistently with previous publications (De Palma et al, 2008; Escobar et al, 2014). Here, TEK is linked to neoplasm.